Loading...
A PET study in healthy subjects of brain exposure of (11)C-labelled osimertinib – A drug intended for treatment of brain metastases in non-small cell lung cancer
Osimertinib is a tyrosine kinase inhibitor (TKI) of the mutated epidermal growth factor receptor (EGFRm) with observed efficacy in patients with brain metastases. Brain exposure and drug distribution in tumor regions are important criteria for evaluation and confirmation of CNS efficacy. The aim of...
Saved in:
| Published in: | J Cereb Blood Flow Metab |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Language: | Inglês |
| Published: |
SAGE Publications
2019
|
| Subjects: | |
| Online Access: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7168784/ https://ncbi.nlm.nih.gov/pubmed/31006308 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/0271678X19843776 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|